Cargando…
Biomarkers in the era of targeted therapy in giant cell arteritis and polymyalgia rheumatica: is it possible to replace acute-phase reactants?
Research into giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) has become more important in the last few decades. Physicians are facing several challenges in managing the diagnosis, treatment, and relapses of GCA and PMR patients. The search for biomarkers could provide elements to guide...
Autores principales: | Carvajal Alegria, Guillermo, Nicolas, Mathilde, van Sleen, Yannick |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313393/ https://www.ncbi.nlm.nih.gov/pubmed/37398679 http://dx.doi.org/10.3389/fimmu.2023.1202160 |
Ejemplares similares
-
Aberrant phenotype of circulating antigen presenting cells in giant cell arteritis and polymyalgia rheumatica
por: Reitsema, Rosanne D., et al.
Publicado: (2023) -
Leukocyte Dynamics Reveal a Persistent Myeloid Dominance in Giant Cell Arteritis and Polymyalgia Rheumatica
por: van Sleen, Yannick, et al.
Publicado: (2019) -
Is Tocilizumab Effective and Safe in Polymyalgia Rheumatica and Giant-Cell Arteritis With Polymyalgia Rheumatica?
por: Farinango, Michelle, et al.
Publicado: (2022) -
Optimal management of giant cell arteritis and polymyalgia rheumatica
por: Charlton, Rodger
Publicado: (2012) -
Genetic epidemiology: Giant cell arteritis and polymyalgia rheumatica
por: Gonzalez-Gay, Miguel A
Publicado: (2001)